Doose, Arne
Tam, Friederike I.
Hellerhoff, Inger
King, Joseph A.
Boehm, Ilka
Gottloeber, Kim
Wahl, Hannes
Werner, Annett
Raschke, Felix
Bartnik-Olson, Brenda
Lin, Alexander P.
Akgün, Katja
Roessner, Veit
Linn, Jennifer
Ehrlich, Stefan http://orcid.org/0000-0003-2132-4445
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EH 367/5-1, SFB 940/2)
B. Braun-Stiftung
Article History
Received: 28 October 2022
Revised: 2 August 2023
Accepted: 3 August 2023
First Online: 12 August 2023
Competing interests
: F.I.T. and S.E. have received a research grant from the “Marga and Walter Boll-Stiftung”. F.I.T. has received funding from the Medical Faculty of the Technische Universität Dresden (“Habilitation Funding for Women”). V.R. has received payment for consulting and writing activities from Eli Lilly and Co., Novartis and Shire Pharmaceuticals/Takeda, lecture honoraria from Eli Lilly and Co., Novartis, Shire Pharmaceuticals/Takeda, and Medice Pharma, and support for research from Shire Pharmaceuticals/Takeda and Novartis. V.R. has carried out (and is currently carrying out) clinical trials in cooperation with Novartis, Shire Pharmaceuticals/Takeda and Otsuka. V.R. has no financial relationship with the organizations that sponsored the research. V.R. has received lecture honoraria from Infectopharm and Medice companies. He has carried out clinical trials in cooperation with Servier and Shire Pharmaceuticals/Takeda companies. K.A. received personal compensation from Novartis, Biogen Idec, Teva, Sanofi, and Roche for consulting service. J.L. serves as advisory boardmember for Biogen GmbH and Mediaire GmbH. A.P.L. is a consultant for Agios Pharmaceuticals, Biomarin Pharmaceuticals, and Moncton MRI; is co-founder of BrainSpec; and receives research funding from NINDS, NIA, the Department of Defense, and the Alzheimer’s Association. A.D., I.H., J.K, I.B, K.G, H.W., A.W., F.R., and B.B. declare no conflicts of interest.